PYY3‐36 as an anti‐obesity drug target

Mary M. Boggiano(University of Alabama at Birmingham), M. Tschöp(University Hospital Münster), Tamara R. Castañeda(German Institute of Human Nutrition), Corinna Schoelch(Boehringer Ingelheim (Germany)), Carsten E. Stidsen(Novo Nordisk (Denmark)), Paula Chandler‐Laney(University of Alabama at Birmingham), Michael D. Culler(Ipsen (United States)), Heather Halem(Ipsen (United States)), Jiawen Dong(Ipsen (United States)), Sylvia Ortmann(German Institute of Human Nutrition), John E. Blundell(University of Leeds), John E. Taylor(The University of Sydney), A. H. Beattie(University of Leeds), Hans‐Georg Joost(German Institute of Human Nutrition), Susanne Klaus(University of Potsdam), Rakesh Datta(Ipsen (France)), Marc Birringer, K. Madsen(Novo Nordisk (Denmark)), David B. Allison(University of Illinois Chicago), Kirsten Arndt(Boehringer Ingelheim (Germany)), Kirsten Raun(Novo Nordisk (Denmark)), Randy J. Seeley(University of Michigan), Annette G. Beck‐Sickinger(Leipzig University of Applied Sciences), Oliver J. Kreuzer, Birgitte S. Wulff(Novo Nordisk (Denmark)), Xiaoying Deng(University of Pittsburgh), Christa Thöne‐Reineke(Charité - Universitätsmedizin Berlin), Michael Mark(Boehringer Ingelheim (Germany)), Yasuyuki Ishii(University of Leeds), R.J. Rodgers(University of Leeds), K Rudolf, S.C. Benoit(University of Cincinnati), D. C. Whitcomb(University of Pittsburgh), M. Schindler(Boehringer Ingelheim (Germany)), Norman Koglin(Piramal (Germany)), Kimberly D. Oswald(University of Alabama at Birmingham), Patricia Holch(University of Leeds)
Obesity Reviews
October 20, 2005
Cited by 121


Related Papers